Home > Blog > Full service phase ii cancer trial

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Success Stories Oncology Biologics Full-Service

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. 

In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including: 
  • Slow recruitment
  • Data cleansing post-MSU
  • Multi-site location, process, and staffing
DOWNLOAD

 

Meet Veristat. Learn More.


 

2 min read

Meet Veristat at the ASCO Annual Meeting

May 5, 2026  Veristat Events

May 29 - June 2, 2026 | Chicago, IL

▶️ At the Forefront of Oncology Progress 

Veristat is pleased to attend the ASCO...

1 min read

Connect with Veristat at OCT East Coast

Apr 30, 2026  Veristat Events

May 12-13, 2026 – New Brunswick, NJ

⚛️ Where Clinical Operations Meet Real-World Execution

Veristat is pleased to...